For early diagnosis of AD and other neurodegenerative diseases, as well as the development of target-specific therapies for these disorders, it is necessary to understand at the molecular and cellular levels how tau initiates the formation of detrimental tauopathies. Here, MAPT is linked to neurodegenerative disease.